[go: up one dir, main page]

MX2022014792A - Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. - Google Patents

Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.

Info

Publication number
MX2022014792A
MX2022014792A MX2022014792A MX2022014792A MX2022014792A MX 2022014792 A MX2022014792 A MX 2022014792A MX 2022014792 A MX2022014792 A MX 2022014792A MX 2022014792 A MX2022014792 A MX 2022014792A MX 2022014792 A MX2022014792 A MX 2022014792A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
cocrystals
treatment methods
methods involving
treating cancer
Prior art date
Application number
MX2022014792A
Other languages
English (en)
Inventor
Chong-Hui Gu
Benjamin S Lane
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2022014792A publication Critical patent/MX2022014792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan formas sólidas de un compuesto útil para tratar el cáncer, composiciones farmacéuticas del mismo y métodos para tratar el cáncer que comprenden administrar las formas sólidas descritas en la presente descripción a un paciente que lo necesita.
MX2022014792A 2017-11-02 2020-07-13 Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. MX2022014792A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02

Publications (1)

Publication Number Publication Date
MX2022014792A true MX2022014792A (es) 2023-01-16

Family

ID=64572453

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004513A MX2020004513A (es) 2017-11-02 2018-11-02 Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX2022014792A MX2022014792A (es) 2017-11-02 2020-07-13 Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004513A MX2020004513A (es) 2017-11-02 2018-11-02 Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.

Country Status (17)

Country Link
US (3) US11345677B2 (es)
EP (1) EP3704101A1 (es)
JP (3) JP7335877B2 (es)
KR (2) KR20240166601A (es)
CN (2) CN118359585A (es)
AU (2) AU2018360827B2 (es)
BR (1) BR112020008598A2 (es)
CA (1) CA3081535A1 (es)
EA (1) EA202091112A1 (es)
IL (2) IL274123B2 (es)
MA (1) MA50526A (es)
MX (2) MX2020004513A (es)
PH (1) PH12020550462A1 (es)
SG (1) SG11202003612VA (es)
TW (2) TWI796377B (es)
UA (1) UA127380C2 (es)
WO (1) WO2019090059A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
WO2022036033A2 (en) 2020-08-12 2022-02-17 Servier Pharmaceuticals, Llc Solid state forms of an organic compound
US20230346789A1 (en) 2022-03-31 2023-11-02 Msd International Gmbh Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
US20250257050A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710636A (en) * 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
CA3081535A1 (en) 2019-05-09
US20220363661A1 (en) 2022-11-17
AU2018360827B2 (en) 2024-02-22
JP7499377B2 (ja) 2024-06-13
TW201930285A (zh) 2019-08-01
IL274123A (en) 2020-06-30
US11851417B2 (en) 2023-12-26
IL305426B2 (en) 2024-10-01
JP2021501766A (ja) 2021-01-21
US20240343705A1 (en) 2024-10-17
EA202091112A1 (ru) 2020-07-23
IL274123B2 (en) 2024-01-01
PH12020550462A1 (en) 2021-03-22
US11345677B2 (en) 2022-05-31
TWI796377B (zh) 2023-03-21
SG11202003612VA (en) 2020-05-28
JP2023093666A (ja) 2023-07-04
JP7780576B2 (ja) 2025-12-04
EP3704101A1 (en) 2020-09-09
KR102731624B1 (ko) 2024-11-19
TWI839131B (zh) 2024-04-11
UA127380C2 (uk) 2023-08-02
JP2024113028A (ja) 2024-08-21
JP7335877B2 (ja) 2023-08-30
MA50526A (fr) 2020-09-09
IL305426A (en) 2023-10-01
TW202337885A (zh) 2023-10-01
CN111527076B (zh) 2024-03-12
US20210198234A1 (en) 2021-07-01
WO2019090059A1 (en) 2019-05-09
AU2024203186A1 (en) 2024-05-30
KR20240166601A (ko) 2024-11-26
IL305426B1 (en) 2024-06-01
AU2018360827A1 (en) 2020-05-14
IL274123B1 (en) 2023-09-01
CN111527076A (zh) 2020-08-11
MX2020004513A (es) 2020-09-17
BR112020008598A2 (pt) 2021-01-26
CN118359585A (zh) 2024-07-19
KR20200095480A (ko) 2020-08-10

Similar Documents

Publication Publication Date Title
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2018000872A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.